# Marsh & McLennan Companies share price today (Marsh & McLennan Companies, Inc., MRSH)

> Marsh & McLennan Companies, Inc. grows steadily. It earns returns above 15% with few surprises. MRSH · Financials · Insurance Brokers · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/mrsh

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $203.63 (+14.3% in a year)
- P/BV: 6.6× (lower than 76% of the last 5.3 years)
- Revenue (Sep 2026): $6.9 B (+8.1% on a year ago)
- Profit (Sep 2026): $812 M (+7.3% on a year ago)
- Net margin: 11.8% (−0.1 points on a year ago)
- ROE: 27%, FY25
- ROA: 7.35%, latest

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Marsh & McLennan Companies share price today? Marsh & McLennan Companies, Inc.'s share price was $203.63 at the close on 3 November 2026. It has been stalling near its high for 4 weeks. That is 14.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $160 and $204, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 4 weeks in a row. Over the last 10 years the share price moved +203% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Marsh & McLennan Companies pay? Marsh & McLennan Companies, Inc. paid $3.78 per share over the last four reported quarters. The most recent declaration was $0.99 for Sep 2026. At today's price of $203.63 that is a yield of 1.86%, based on dividends already paid, not a forecast. ## Which stock lists is Marsh & McLennan Companies on? Marsh & McLennan Companies is on one of our US lists: S&P 500 companies. [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Marsh & McLennan Companies profitable? Marsh & McLennan Companies, Inc. earned $812 M of net profit in the Sep 2026 quarter, +7.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $4.2 B. Over 4 years profit has grown 7.5% a year on average. That is 11.8% of the quarter's revenue. The same quarter a year earlier earned $757 M. For the full year, FY25 profit was $4.2 B (+2.8% on the year before). Why profit moved: revenue changed +8.1% on a year earlier and the margin moved −0.1 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +0.1% and revenue +7.6%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Marsh & McLennan Companies make, and is it growing? Marsh & McLennan Companies, Inc. reported $6.9 B of income in the Sep 2026 quarter, +8.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 8.0% a year on average. The last full year, FY25, came in at $27.0 B. The last four reported quarters add to $28.5 B. FY25 revenue was $27.0 B, +10.3% on the year before. Recent pace: the last four quarters grew +7.6% on average, against 8.0% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +7.6%, against +9.0% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −1.9%, against +0.5% a year (stabilising). ## How much does Marsh & McLennan Companies keep from what it earns? Marsh & McLennan Companies, Inc.'s net margin was 11.8% in the Sep 2026 quarter, 0.1 percentage points lower than the same quarter a year ago. Across 5 years it has been between 14.9% and 16.8%. The latest quarter is below every full year in that period. Why: the net margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## How many of Marsh & McLennan Companies' loans have gone bad? Marsh & McLennan Companies, Inc. does not report loan-quality figures this page can read, so this section says so rather than guess. No bad-loan figures are filed in a form this page can read, and none are guessed from the profit line. The income, margin and return sections carry what this business does report. Why: loan quality drives a lender, but its details (new bad loans, recoveries, money set aside) are not in our data for this company. The sections around this one carry what we can back up. ## How fast is Marsh & McLennan Companies' loan book growing? Marsh & McLennan Companies, Inc.'s revenue was $27.0 B in FY25, +10.3% on the year before, so the loan book is growing. The latest quarter was +8.1% on a year earlier. The net margin on that income is 11.8%, −0.1 percentage points on a year ago. Interest income stands in for the size of the loan book; changes in interest rates can move it a few points in any year. In short: a lender grows well when its loan book grows, its margin stays steady and its loans stay clean. Quarterly loan-quality figures are missing here, so revenue growth and margin are the two we watch. ## What is Marsh & McLennan Companies' P/BV ratio, and how does it compare with its own history? Marsh & McLennan Companies, Inc.'s P/BV is 6.6×, near the low end of its own history: it has been lower only 24% of the time. Its usual P/BV (the middle reading) is 7.8×, over 5.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year book value grew while the price moved +14.3%. Price and book value moved together, so the multiple stayed in its range. Where the price move came from: over 5 years the price moved +4.8% a year; about +10.2% a year came from book-value growth and about −5.4 percentage points from the multiple (the market paying less). The split is approximate (price return minus book-value growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the book value trend underneath matters more than the multiple. ## Is the Marsh & McLennan Companies business getting better or worse? Marsh & McLennan Companies, Inc.'s business is giving mixed signals. There is no clear direction across the growth lines, with ROE steady at 27.7%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Marsh & McLennan Companies earn on its equity and assets? Marsh & McLennan Companies, Inc. earned a return on equity of 28% in FY25. That is its lowest yearly reading on file. On its assets, every $100 earned about $7.35, before the effect of borrowing. For a lender the balance sheet is the business, so the return on equity and on assets have to be read together. That is above the level a bank needs to grow its net worth steadily. Why: the ROE chart shows the move, but the deposit-cost and bad-loan details behind it are not in our data. ## Does Marsh & McLennan Companies have too much debt? For a bank, borrowing is the raw material of the business, not a warning sign: it borrows money in order to lend it out. Its safety is read through its returns and its loans. Its safety is read from the bad-loan figures and the return on equity instead. For a manufacturer, debt is a claim on its profits. For a lender it is the stock it trades in, so the usual debt-to-equity test would mislead and is not used here. ## What is the Marsh & McLennan Companies shareholding pattern? 1.4% of Marsh & McLennan Companies, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 2.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Marsh & McLennan Companies from balance-sheet trouble? For Marsh & McLennan Companies, Inc., the Z-score is not used, because it was built for manufacturers, not lenders. For a lender, safety is read from its capital and bad-loan figures instead. ## How does Marsh & McLennan Companies rank in its industry? 55.8 out of 100, rank 5 of 15 in Insurance Brokers, with 80% of the evidence available. Marsh & McLennan Companies, Inc. scores 55.8 out of 100 against the 15 companies it is compared with in Insurance Brokers, ranking 5. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 15.5 + 17.8 + 10.3 + 12.2 = 55.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if ROA turns down or gross NPA rises while the share price lags its sector. ## Which companies is Marsh & McLennan Companies compared with? Marsh & McLennan Companies ranks 5 of 15 Insurance Brokers companies on the 4-Factor Sector Score, with 55.8 out of 100. 1. [TWFG, Inc.](https://www.sectoralpha.in/us/stocks/twfg) TWFG · turning · Most evidence points up · 76% evidence 73.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.4/35 · Income 34.7% · Profit 80.7% · 71% evidence Capital efficiency 16.6/25 · ROA 8.3% · ROE 16.8% · GNPA n/a · 68% evidence Valuation 16.0/20 · P/BV 1.09× · P/BV÷ROE 0.07 · 70% evidence Relative strength 12.7/20 · Lead over its industry 3.7% · Lead over S&P 500 13.5% · 1 year 13.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 28.4 + 16.6 + 16 + 12.7 = 73.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [CorVel Corporation](https://www.sectoralpha.in/us/stocks/crvl) CRVL · breaking out · Evidence leans up · 76% evidence 59.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.1/35 · Income 7.2% · Profit 15% · 71% evidence Capital efficiency 19.4/25 · ROA 15.4% · ROE 32.2% · GNPA n/a · 68% evidence Valuation 5.2/20 · P/BV 7.8× · P/BV÷ROE 0.24 · 70% evidence Relative strength 18.9/20 · Lead over its industry 11.2% · Lead over S&P 500 22.2% · 1 year 8.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 16.1 + 19.4 + 5.2 + 18.9 = 59.6 · What this means: Relative strength against the index is 22.2%, and revenue and profit growth are weak. 3. [Brown & Brown, Inc.](https://www.sectoralpha.in/us/stocks/bro) BRO · turning · Evidence leans up · 76% evidence 56.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Income 34.6% · Profit 19.7% · 71% evidence Capital efficiency 14.2/25 · ROA 7.4% · ROE 13.6% · GNPA n/a · 68% evidence Valuation 13.7/20 · P/BV 1.73× · P/BV÷ROE 0.13 · 70% evidence Relative strength 6.3/20 · Lead over its industry -11.8% · Lead over S&P 500 -2.8% · 1 year -9.7% · 100% evidence · 6 of 12 weeks ahead Exact sum: 22 + 14.2 + 13.7 + 6.3 = 56.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Arthur J. Gallagher & Co.](https://www.sectoralpha.in/us/stocks/ajg) AJG · turning · Evidence leans up · 76% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.4/35 · Income 30.8% · Profit -4.5% · 71% evidence Capital efficiency 13.4/25 · ROA 4.4% · ROE 14% · GNPA n/a · 68% evidence Valuation 9.8/20 · P/BV 2.48× · P/BV÷ROE 0.18 · 70% evidence Relative strength 14.5/20 · Lead over its industry -0.4% · Lead over S&P 500 9.7% · 1 year 9.4% · 100% evidence · 8 of 12 weeks ahead Exact sum: 18.4 + 13.4 + 9.8 + 14.5 = 56.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. Marsh & McLennan Companies, Inc. this page MRSH · turning · Evidence leans up · 80% evidence 55.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.5/35 · Income 7.6% · Profit -1.9% · 81% evidence Capital efficiency 17.8/25 · ROA 8.2% · ROE 34.2% · GNPA n/a · 68% evidence Valuation 10.3/20 · P/BV 5.46× · P/BV÷ROE 0.16 · 70% evidence Relative strength 12.2/20 · Lead over its industry -2.2% · Lead over S&P 500 8.1% · 1 year 13.1% · 100% evidence · 6 of 12 weeks ahead Exact sum: 15.5 + 17.8 + 10.3 + 12.2 = 55.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Goosehead Insurance, Inc.](https://www.sectoralpha.in/us/stocks/gshd) GSHD · basing · Evidence leans up · 64% evidence 54.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Income 17.6% · Profit 16.7% · 71% evidence Capital efficiency 18.6/25 · ROA 9.2% · ROE 461.2% · GNPA n/a · 68% evidence Valuation 10.9/20 · P/BV -6.09× · P/BV÷ROE n/a · 10% evidence Relative strength 0.4/20 · Lead over its industry -16.9% · Lead over S&P 500 -9.4% · 1 year -24.9% · 100% evidence · 5 of 12 weeks ahead Exact sum: 24.5 + 18.6 + 10.9 + 0.4 = 54.4 · What this means: Earnings are strong; relative strength in its sector is -16.9% and the one-year return is -24.9%. 7. [Aon plc](https://www.sectoralpha.in/us/stocks/aon) AON · basing · Evidence leans up · 76% evidence 51.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.5/35 · Income 4.9% · Profit 49.3% · 71% evidence Capital efficiency 18.9/25 · ROA 8.8% · ROE 50.8% · GNPA n/a · 68% evidence Valuation 11.2/20 · P/BV 7.3× · P/BV÷ROE 0.14 · 70% evidence Relative strength 1.5/20 · Lead over its industry -14.3% · Lead over S&P 500 -5.2% · 1 year -4.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 19.5 + 18.9 + 11.2 + 1.5 = 51.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Willis Towers Watson Public Limited Company](https://www.sectoralpha.in/us/stocks/wtw) WTW · quiet · Evidence leans up · 76% evidence 50.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Income 3% · Profit 100% · 71% evidence Capital efficiency 13.4/25 · ROA 4.2% · ROE 15% · GNPA n/a · 68% evidence Valuation 7.4/20 · P/BV 3.18× · P/BV÷ROE 0.21 · 70% evidence Relative strength 7.0/20 · Lead over its industry -6.7% · Lead over S&P 500 2.9% · 1 year 0.5% · 100% evidence · 6 of 12 weeks ahead Exact sum: 22.6 + 13.4 + 7.4 + 7 = 50.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Accelerant Holdings](https://www.sectoralpha.in/us/stocks/arx) ARX · leader · Evidence leans down · 64% evidence 47.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.8/35 · Income 55.5% · Profit -3137.8% · 71% evidence Capital efficiency 5.3/25 · ROA -0.2% · ROE -2.3% · GNPA n/a · 68% evidence Valuation 9.6/20 · P/BV 3.44× · P/BV÷ROE n/a · 10% evidence Relative strength 20.0/20 · Lead over its industry 13.5% · Lead over S&P 500 24.9% · 1 year 56.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 12.8 + 5.3 + 9.6 + 20 = 47.7 · What this means: Relative strength against the index is 24.9%, and revenue and profit growth are weak. 10. [Erie Indemnity Company](https://www.sectoralpha.in/us/stocks/erie) ERIE · turning · Evidence leans down · 76% evidence 45.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Income 3.7% · Profit -7.8% · 71% evidence Capital efficiency 18.7/25 · ROA 12.7% · ROE 26% · GNPA n/a · 68% evidence Valuation 8.2/20 · P/BV 5.08× · P/BV÷ROE 0.2 · 70% evidence Relative strength 9.0/20 · Lead over its industry -8.5% · Lead over S&P 500 1% · 1 year -5.3% · 100% evidence · 8 of 12 weeks ahead Exact sum: 10 + 18.7 + 8.2 + 9 = 45.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [The Baldwin Insurance Group, Inc.](https://www.sectoralpha.in/us/stocks/bwin) BWIN · leader · Too little evidence to rank firmly · 55% evidence 45.0 out of 100 Growth Capital Valuation Relative
12. [Crawford & Company](https://www.sectoralpha.in/us/stocks/crd-a) CRD-A · quiet · Most evidence points down · 76% evidence 25.1 out of 100 Growth Capital Valuation Relative
13. SelectQuote, Inc. SLQT · Too little evidence to rank firmly · 47% evidence 62.8 out of 100 Growth Capital Valuation Relative
14. [Neptune Insurance Holdings Inc.](https://www.sectoralpha.in/us/stocks/np) NP · quiet · Too little evidence to rank firmly · 41% evidence 52.0 out of 100 Growth Capital Valuation Relative
15. [Ethos Technologies Inc.](https://www.sectoralpha.in/us/stocks/life) LIFE · breaking out · Too little evidence to rank firmly · 44% evidence 39.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Insurance Brokers](https://www.sectoralpha.in/us/sectors/insurance-brokers), all 15 compared on one page. ## Which companies are close to Marsh & McLennan Companies in size? Marsh & McLennan Companies is the largest of 14 Insurance Brokers companies on Sector Alpha by market value (scores of 3 November 2026). It is the largest. Just below it: Arthur J. Gallagher & Co., Aon plc, Willis Towers Watson Public Limited Company, Brown & Brown, Inc., Erie Indemnity Company and The Baldwin Insurance Group, Inc. ### Insurance Brokers companies close in size

1. Marsh & McLennan Companies, Inc. $96.8 billion
2. [Arthur J. Gallagher & Co.](https://www.sectoralpha.in/us/stocks/ajg) $70.1 billion
3. [Aon plc](https://www.sectoralpha.in/us/stocks/aon) $70 billion
4. [Willis Towers Watson Public Limited Company](https://www.sectoralpha.in/us/stocks/wtw) $30.2 billion
5. [Brown & Brown, Inc.](https://www.sectoralpha.in/us/stocks/bro) $23.5 billion
6. [Erie Indemnity Company](https://www.sectoralpha.in/us/stocks/erie) $14.1 billion
7. [The Baldwin Insurance Group, Inc.](https://www.sectoralpha.in/us/stocks/bwin) $4.5 billion

[All 14 Insurance Brokers companies, largest first](https://www.sectoralpha.in/us/sectors/insurance-brokers#all-companies)

### Companies close in size in other industries

1. [Equinix, Inc.](https://www.sectoralpha.in/us/stocks/eqix) $98.4 billion · REIT - Specialty
2. [HCA Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/hca) $97.7 billion · Medical Care Facilities
3. Marsh & McLennan Companies, Inc. $97.7 billion
4. [GSK plc](https://www.sectoralpha.in/us/stocks/gsk) $97.4 billion · Drug Manufacturers - General
5. [Adobe Inc.](https://www.sectoralpha.in/us/stocks/adbe) $97.4 billion · Software - Application

## What else do people ask about Marsh & McLennan Companies? ### What were Marsh & McLennan Companies's latest quarterly results? Marsh & McLennan Companies, Inc. reported total income of $6.9 B and net profit of $812 M for the Sep 2026 quarter. Income rose 8.1% and profit rose 7.3% compared with a year earlier. Earnings per share were $1.69 (as of 3 November 2026). ### What is Marsh & McLennan Companies's market cap? Marsh & McLennan Companies, Inc.'s market capitalisation is $96.8 B at a stock price of $203.63. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Marsh & McLennan Companies performing? Marsh & McLennan Companies, Inc.'s share price has been stalling near its high for 4 weeks. In its latest quarter, income rose 8.1% and profit rose 7.3% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 4 weeks running (as of 3 November 2026). ### Will Marsh & McLennan Companies's stock price go up? This page does not forecast Marsh & McLennan Companies, Inc.'s stock price. What it shows instead: the stock price is $203.63, and it has been stalling near its high for 4 weeks. Its P/BV of 6.6× is higher than 24% of its own last 5 years (as of 3 November 2026). ### Where is Marsh & McLennan Companies in its business cycle? Marsh & McLennan Companies, Inc.'s FY25 net margin was 15.7%, against a 5-year range of 14.9% to 16.8%: the middle of its own range, neither a peak nor a low. The latest quarter was 11.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Marsh & McLennan Companies story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Marsh & McLennan Companies a stock worth studying right now? What the numbers show: Marsh & McLennan Companies, Inc. grows steadily. It earns returns above 15% with few surprises. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.